Drug
TAB08
TAB08 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
4
80%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
completed480%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
NCT03006029
terminatedphase_2
TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
NCT02711813
completedphase_1
Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis
NCT01990157
completedphase_1
Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers
NCT01885624
completedphase_1
TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
NCT02796053
Clinical Trials (5)
Showing 5 of 5 trials
NCT03006029Phase 1
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
NCT02711813Phase 2
TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment
NCT01990157Phase 1
Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis
NCT01885624Phase 1
Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers
NCT02796053Phase 1
TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5